查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840674

子宮肌瘤治療設備市場（按產品類型、技術、最終用戶和分銷管道）—2025 年至 2032 年全球預測

Uterine Fibroid Treatment Device Market by Product Type, Technology, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年子宮肌瘤治療設備市場將成長至 13.9779 億美元，複合年成長率為 10.73%。

主要市場統計數據
基準年2024年 6.1832億美元
預計2025年 6.842億美元
預測年份：2032年 13.9779億美元
複合年成長率（%） 10.73%

重點介紹概述了重新定義子宮肌瘤治療設備採用的臨床要求、病人歷程影響和創新促進因素

子宮肌瘤是最常見的婦科良性疾病之一，其器械領域的不斷發展反映了微創、以患者為中心的治療模式的轉變。臨床醫生越來越重視能夠緩解症狀、保留生育能力並縮短復原時間的手術。這種臨床需求，加上患者對門診治療的偏好，促使人們開發和改進能夠降低手術全期風險並最大程度縮短住院時間的技術。

同時，技術進步和程序創新正在擴展醫生可用的治療套件，創建一個更細緻的決策矩陣，該矩陣受子宮肌瘤的大小、數量和位置、患者年齡以及生育目標的影響。隨著相關人員評估循證策略以支持新的和擴展的適應症，監管途徑和報銷考慮進一步影響了藥物的採用。因此，市場參與企業必須妥善處理臨床證據、設備性能和醫療保健系統經濟學之間複雜的相互作用，才能在這種動態環境中取得成功。

不斷變化的臨床重點、患者期望和價值主導的護理模式如何重塑子宮肌瘤治療技術的競爭動態

受臨床重點、技術創新和醫療服務模式轉變的推動，子宮肌瘤治療器材的市場模式正在發生重大變化。隨著越來越多的證據顯示微創手術比傳統手術方法更安全有效，其應用也日益廣泛。能量療法和影像導引系統的創新擴大了微創手術的適應症，並使手術能夠在門診進行，從而縮短患者恢復時間並降低併發症發生率。

同時，患者的期望也在不斷演變。資訊獲取管道的改善以及對保留生育能力治療方案日益成長的偏好，促使臨床醫生重新思考傳統的治療方法。為此，醫療系統已建立專科路徑和卓越中心，以集中專業知識並改善治療效果。此外，付款人監督和基於價值的合約模式正在獎勵那些在短期康復和長期生活品質方面表現出顯著改善的設備和程序。因此，競爭格局有利於擁有可靠臨床證據、明確價值提案和可擴展商業化策略的製造商。

評估 2025 年實施的美國關稅對醫療設備採購、定價和打入市場策略的連鎖營運和商業影響

2025年實施的關稅政策和貿易行動對美國國內醫療設備供應鍊和商業化策略產生了多重影響。某些零件和成品的進口關稅上調，迫使製造商和經銷商重新評估籌資策略，在可行的情況下優先考慮本地化，並重新協商供應商合約以緩解成本壓力。這些調整導致了一系列營運變革，包括重新評估庫存管理和修改產品上市前置作業時間假設。

雖然臨床應用決策是基於安全性和有效性，但增加的成本和物流複​​雜性影響了定價策略以及與醫療系統的合約談判。在某些情況下，醫療保健機構加快了國內製造夥伴關係計劃，或在相關市場尋找替代零件供應商，以保護利潤率並保持價格競爭力。展望未來，整合靈活的供應鏈架構、透明的成本模型和積極主動的相關人員溝通的製造商將能夠更好地應對關稅波動，並保持進入美國臨床市場的管道。

有針對性的細分洞察，揭示產品類型、技術、醫療保健環境和分銷管道的交叉點，從而影響臨床應用和商業性重點

細分市場動態提供了跨裝置類型和技術平台的臨床實踐和購買行為的細緻視角。基於產品類型的市場分析考慮了高強度聚焦超音波、子宮切除術、子宮肌瘤切除術、射頻消融術和子宮動脈栓塞術，其中肌瘤摘除進一步分為腹腔鏡、腹部和陰道入路，肌瘤摘除術又分為子子宮鏡、腹腔鏡和開放入路。每種產品都針對不同的臨床場景和患者偏好，對於合適的患者，侵入性較小的治療方案越來越受到青睞。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將即時MRI引導整合到子宮肌瘤消融手術中
  • 可生物分解栓塞微球的開發用於子宮肌瘤標靶治療
  • 門診中心擴大採用門診射頻消融術系統
  • 機器人輔助子宮肌瘤切除術的進展提高了手術精度
  • 增加對美國微創子宮肌瘤治療設備Start-Ups的投資
  • 監管部門的核准加速了新型子宮肌瘤管理設備的市場進入
  • 年輕女性對無痛子宮頸超音波消融術的需求日益成長
  • 設備製造商與人工智慧公司合作進行預測性治療
  • 一次性子宮鏡平台的創新降低了交叉污染的風險
  • 專注於針對特定患者的 3D 列印模型，用於術前子宮肌瘤治療計劃

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：子宮肌瘤治療設備市場（依產品類型）

  • 高強度聚焦超音波
  • 子宮切除術
    • 腹部
    • 腹腔鏡
    • 陰道
  • 子宮肌瘤切除術
    • 子宮鏡檢查
    • 腹腔鏡
    • 打開
  • 射頻消融
  • 子宮動脈栓塞術

9. 子宮肌瘤治療設備市場（依技術）

  • 冷凍療法
  • 高強度聚焦超音波
  • 微波消融
  • 射頻消融

第 10 章子宮肌瘤治療設備市場（依最終用戶）

  • 門診手術中心
  • 診所
  • 醫院
  • 子宮肌瘤專科中心

第11章子宮肌瘤治療設備市場（依通路）

  • 直銷
  • 經銷商
  • 電子商務

第12章子宮肌瘤治療器械市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章子宮肌瘤治療設備市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章子宮肌瘤治療設備市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Johnson & Johnson
    • Medtronic plc
    • Hologic, Inc.
    • Boston Scientific Corporation
    • Olympus Corporation
    • GE HealthCare Technologies Inc.
    • Siemens Healthineers AG
    • Merit Medical Systems, Inc.
    • Insightec Ltd.
    • Chongqing Haifu MedTech Co., Ltd.
Product Code: MRR-0360AB17E12E

The Uterine Fibroid Treatment Device Market is projected to grow by USD 1,397.79 million at a CAGR of 10.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 618.32 million
Estimated Year [2025] USD 684.20 million
Forecast Year [2032] USD 1,397.79 million
CAGR (%) 10.73%

A focused introduction outlining clinical imperatives, patient journey influences, and innovation drivers redefining uterine fibroid treatment device adoption

Uterine fibroids represent one of the most common benign gynecologic conditions, and the evolving device landscape reflects a shift toward less invasive, patient-centered care. Clinicians increasingly prioritize procedures that deliver symptom relief while preserving fertility and reducing recovery time. These clinical imperatives, combined with patient demand for outpatient options, have catalyzed the development and refinement of technologies that mitigate perioperative risks and minimize hospital stays.

In parallel, technological advancements and procedural innovation have expanded the therapeutic toolkit available to physicians, creating a more nuanced decision matrix influenced by fibroid size, number, location, patient age, and reproductive goals. Regulatory pathways and reimbursement considerations further shape adoption, as stakeholders evaluate evidence generation strategies to support new indications and label expansions. Consequently, market participants must navigate a complex interplay of clinical evidence, device performance, and health-system economics to succeed in this dynamic environment.

How shifts in clinical priorities, patient expectations, and value-driven care models are reshaping the competitive dynamics of uterine fibroid treatment technologies

The landscape for uterine fibroid treatment devices has undergone transformative shifts driven by clinical priorities, technological innovation, and changing care delivery models. Minimally invasive procedures have gained traction as evidence accumulates on their safety and efficacy compared with traditional surgical approaches. Innovations in energy-based modalities and image-guided systems have expanded indications and enabled procedures to be performed in ambulatory settings with faster recovery and lower complication profiles.

Simultaneously, patient expectations have evolved; greater access to information and a preference for fertility-preserving options have led clinicians to reconsider historical default treatments. Health systems have responded by establishing specialized pathways and centers of excellence to concentrate expertise and improve outcomes. Moreover, payer scrutiny and value-based contracting have incentivized devices and procedures that demonstrate measurable improvements in short-term recovery and long-term quality of life. As a result, the competitive terrain favors manufacturers that pair robust clinical evidence with clear value propositions and scalable commercialization strategies.

Evaluating the cascading operational and commercial consequences of United States tariffs introduced in 2025 on device sourcing, pricing, and market access strategies

Tariff policies and trade actions introduced in 2025 have exerted a layered impact on medical device supply chains and commercialization strategies within the United States. Increased import duties on select components and finished devices compelled manufacturers and distributors to reassess sourcing strategies, prioritize localization where feasible, and renegotiate supplier contracts to mitigate cost pressures. These adjustments produced a cascade of operational changes, including inventory management revisions and altered lead-time assumptions for product launches.

Although clinical adoption decisions remain grounded in safety and efficacy, the added cost and logistical complexity have influenced pricing strategies and contract negotiations with health systems. In some cases, organizations accelerated plans for domestic manufacturing partnerships or sought alternative component suppliers in allied markets to preserve margin and maintain competitive pricing. Looking forward, manufacturers that integrate flexible supply chain architectures, transparent cost models, and proactive stakeholder communications will navigate tariff-driven disruptions more effectively and sustain access to the U.S. clinical market.

Targeted segmentation insights revealing where product types, technologies, care settings, and distribution channels intersect to shape clinical adoption and commercial focus

Segment-level dynamics offer a nuanced view of clinical practice and purchasing behavior across device types and technology platforms. Based on Product Type, market analysis considers High Intensity Focused Ultrasound, Hysterectomy, Myomectomy, Radiofrequency Ablation, and Uterine Artery Embolization, with Hysterectomy further categorized into Abdominal, Laparoscopic, and Vaginal approaches and Myomectomy divided into Hysteroscopic, Laparoscopic, and Open techniques. Each product pathway addresses distinct clinical scenarios and patient preferences, with less invasive options increasingly favored for suitable candidates.

Based on Technology, the field is examined through the lens of Cryoablation, High Intensity Focused Ultrasound, Microwave Ablation, and Radiofrequency Ablation, each offering different trade-offs in terms of tissue specificity, procedural duration, and imaging compatibility. Based on End User, the analysis spans Ambulatory Surgical Centers, Clinics, Hospitals, and Specialized Fibroid Centers, revealing how care setting influences device selection, procedural throughput, and reimbursement patterns. Based on Distribution Channel, considerations include Direct Sales, Distributors, and E Commerce, highlighting how channel strategy affects market reach, customer relationships, and adoption velocity. Integrating these segmentation layers clarifies where clinical unmet needs align with technological strengths and where commercial focus can yield the greatest strategic return.

Key regional dynamics and institutional factors across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence device adoption and market entry strategies

Regional dynamics influence regulatory, clinical, and commercial pathways for uterine fibroid treatments in distinct ways that affect product planning and market entry. In the Americas, a concentration of specialized clinical centers, extensive outpatient infrastructure, and robust clinical trial activity support early adoption of innovative, minimally invasive devices, while payer complexity and regional reimbursement variability require adaptive evidence strategies.

Europe, Middle East & Africa presents a heterogeneous environment where regulatory harmonization efforts coexist with diverse public and private payer systems, creating both opportunities for centralized approvals and challenges in localized evidence generation. Adoption in this region often hinges on demonstrating cost-effectiveness within constrained health budgets. Asia-Pacific exhibits rapid infrastructure expansion, growing demand for fertility-preserving interventions, and increasingly sophisticated private healthcare networks; however, market entry strategies must account for varied regulatory timelines, local clinical practice patterns, and government-led initiatives to develop domestic manufacturing capabilities. Understanding these regional contours enables prioritization of regulatory pathways, clinical partnerships, and commercial investments that align with on-the-ground realities.

Insight into competitive behaviors, innovation strategies, and partnership models that determine which companies succeed in the evolving uterine fibroid device ecosystem

The competitive landscape comprises established surgical platform manufacturers, emerging energy-based device innovators, and specialized service providers that together shape clinical options and procurement decisions. Leading companies have concentrated on expanding procedural indications, enhancing imaging integration, and developing modular platforms that serve multiple gynecologic applications. At the same time, smaller, agile firms have focused on niche innovations-improvements in energy delivery, disposable instrumentation, and outpatient workflow optimization-that create entry points against larger incumbents.

Strategic partnerships between device makers and clinical networks have accelerated real-world evidence collection and facilitated rapid feedback loops to refine training and support. Additionally, companies that invest in comprehensive training curricula and digital support tools have seen higher procedure adoption and customer satisfaction. Competitive differentiation increasingly rests on the ability to demonstrate not just clinical efficacy, but also measurable reductions in procedural time, complication rates, and total episode-of-care burden, thereby appealing to both clinicians and value-conscious purchasers.

Actionable recommendations for device manufacturers and stakeholders to accelerate adoption, de-risk supply chains, and align evidence with payer and clinician priorities

Industry leaders should adopt a multi-pronged strategy that balances clinical evidence generation with commercial agility. Prioritize prospective, pragmatic clinical studies that address patient-relevant outcomes and align with payer value frameworks to support favorable coverage decisions. Simultaneously, invest in training programs and procedural support that lower the barrier to adoption among surgeons, interventionalists, and ambulatory care teams, thereby accelerating uptake in outpatient settings.

Operationally, diversify supply chains and consider nearshoring or multi-sourcing strategies to mitigate tariff- and logistics-related risks. Enhance commercial models by tailoring distribution approaches to account for the distinct needs of hospitals, ambulatory surgical centers, clinics, and specialized fibroid centers, while leveraging digital channels to increase market reach. Finally, cultivate collaborations with key opinion leaders, patient advocacy groups, and payers to co-create value propositions that emphasize quality of life improvements and efficient use of health system resources, which will position product portfolios for sustained adoption.

A clear and transparent mixed-methods research methodology combining expert interviews, regulatory review, and evidence triangulation to ensure rigorous, actionable insights

This research adopts a mixed-methods approach combining qualitative interviews with clinicians, procurement leaders, and payers, along with secondary review of regulatory guidance, clinical literature, and policy developments. The methodology emphasizes triangulation: triangulating expert perspectives against procedural guidelines and publicly available clinical evidence to identify convergent themes and areas of divergence. Data validation included cross-referencing procedural trends and technology adoption signals to ensure internal consistency and practical relevance.

Throughout the research process, emphasis was placed on transparency of assumptions and reproducibility of analytic steps. Stakeholder interviews were conducted across care settings and geographies to capture a representative set of perspectives, and methodological limitations were documented to highlight areas where additional primary research could strengthen inference. This approach supports confident, actionable insights while acknowledging the evolving nature of clinical practice and regulatory environments.

Concluding synthesis emphasizing how clinical innovation, supply chain resilience, and evidence alignment will determine long-term success in fibroid device markets

In conclusion, the uterine fibroid treatment device landscape is transitioning toward less invasive, value-oriented care pathways that prioritize patient recovery, fertility preservation, and efficient use of healthcare resources. Technological innovation and procedural refinement have expanded therapeutic choices, creating both opportunities and complexity for clinicians and purchasers. Market success will favor organizations that align clinical evidence generation with pragmatic value propositions and adaptive commercial strategies.

Moreover, external factors such as trade policies and regional heterogeneity in regulatory and reimbursement systems impose operational considerations that cannot be ignored. Stakeholders that proactively address supply chain resilience, invest in clinician training, and engage payers with clear outcome-focused data will be best positioned to capture opportunity and deliver sustained clinical impact. Continued collaboration across manufacturers, clinicians, and health systems will remain essential to translate innovation into improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of real-time MRI guidance in uterine fibroid ablation procedures
  • 5.2. Development of biodegradable embolic microspheres for targeted fibroid therapy
  • 5.3. Rising adoption of outpatient radiofrequency ablation systems by ambulatory centers
  • 5.4. Advancements in robotic-assisted fibroid removal enhancing surgical precision
  • 5.5. Increasing investment in US-based minimally invasive fibroid device startups
  • 5.6. Regulatory approvals accelerating market entry for novel fibroid management devices
  • 5.7. Growing demand for pain-free transcervical ultrasound ablation in young females
  • 5.8. Collaborations between device manufacturers and AI firms for predictive treatment
  • 5.9. Innovations in single-use hysteroscopic platforms reducing cross-contamination risk
  • 5.10. Focus on patient-specific 3D printed models for preoperative fibroid planning

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Uterine Fibroid Treatment Device Market, by Product Type

  • 8.1. High Intensity Focused Ultrasound
  • 8.2. Hysterectomy
    • 8.2.1. Abdominal
    • 8.2.2. Laparoscopic
    • 8.2.3. Vaginal
  • 8.3. Myomectomy
    • 8.3.1. Hysteroscopic
    • 8.3.2. Laparoscopic
    • 8.3.3. Open
  • 8.4. Radiofrequency Ablation
  • 8.5. Uterine Artery Embolization

9. Uterine Fibroid Treatment Device Market, by Technology

  • 9.1. Cryoablation
  • 9.2. High Intensity Focused Ultrasound
  • 9.3. Microwave Ablation
  • 9.4. Radiofrequency Ablation

10. Uterine Fibroid Treatment Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Specialized Fibroid Centers

11. Uterine Fibroid Treatment Device Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. E Commerce

12. Uterine Fibroid Treatment Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Uterine Fibroid Treatment Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Uterine Fibroid Treatment Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Johnson & Johnson
    • 15.3.2. Medtronic plc
    • 15.3.3. Hologic, Inc.
    • 15.3.4. Boston Scientific Corporation
    • 15.3.5. Olympus Corporation
    • 15.3.6. GE HealthCare Technologies Inc.
    • 15.3.7. Siemens Healthineers AG
    • 15.3.8. Merit Medical Systems, Inc.
    • 15.3.9. Insightec Ltd.
    • 15.3.10. Chongqing Haifu MedTech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. UTERINE FIBROID TREATMENT DEVICE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. UTERINE FIBROID TREATMENT DEVICE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. UTERINE FIBROID TREATMENT DEVICE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY VAGINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTEROSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY OPEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY UTERINE ARTERY EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CRYOABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MICROWAVE ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SPECIALIZED FIBROID CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY E COMMERCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY E COMMERCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2018-2024 (USD MILLION)
  • TABLE 284. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY HYSTERECTOMY, 2025-2032 (USD MILLION)
  • TABLE 285. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2018-2024 (USD MILLION)
  • TABLE 286. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY MYOMECTOMY, 2025-2032 (USD MILLION)
  • TABLE 287. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GCC UTERINE FIBROID TREATMENT DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. GCC UTERINE FIBROID TREATMENT DEVICE MARKE